The fate of the world's best-selling cancer medicine is in the hands of the FDA. There's a lot at stake for Roche and the thousands of women who take the drug, reports CNBC's Hampton Pearson.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT